McKesson Corporation Earnings Recaps
Q4 2026
May 8, 2026
McKesson shares declined modestly by 1.0% following its fiscal Q4 2026 report, reflecting investor caution amid a muted outlook for fiscal 2027 despite stable operational execution and ongoing strategic progress.
Key takeaways
- Adjusted earnings per diluted share grew 18% in fiscal 2026, supported by growth across strategic platforms.
- Operating cash flow reached $6.2 billion, surpassing internal plans, with $5.1 billion returned to shareholders.
- Continued progress on Medical-Surgical Solutions separation, including transition service agreements and minority investor partnership with Apollo.
- Fiscal 2027 EPS guidance range set at $43.80 to $44.60, lacking upward revision and suggesting limited near-term earnings acceleration.
- Strategic initiatives such as oncology platform expansion and technology adoption continue, though offset by restrained margin commentary and cautious outlook.
Q3 2026
Feb 5, 2026
McKesson Corporation delivered robust third-quarter results for fiscal 2026, showcasing double-digit revenue and earnings growth driven by continued strength in oncology, biopharma services, and North American distribution. The company raised its full-year EPS guidance, reflecting strong momentum across its strategic initiatives.
Key takeaways
- Revenue and adjusted EPS increased by 17-19% year-over-year, indicating strong business momentum.
- Integration of acquired entities such as Florida Cancer Specialists and Prism Vision enhances McKesson's oncology services and market position.
- Introduction of 50 new programs across diverse brands demonstrates strong demand for patient access and affordability solutions.
- Continued investment in technology improves workflow efficiency, with employees now supporting 120 more patients per full-time staff in annual verification.
- Strong partnerships with manufacturers and advocacy efforts align with the evolving healthcare landscape and regulatory changes.